NBJ
Jellyfish Thinkstock

The rise and fall of America’s best-selling brain health supplement

Supplement critics and consumer watchdog groups have seized on the case of Prevagen as an example of a lack of regulatory scrutiny.

In April, 2012, a little-known supplement made from a protein found in jellyfish was poised for a meteoric rise.

After eight years of raising capital and coordinating studies in petri dishes, dogs, and people, Mark Underwood—who worked as a manager in a chemical manufacturing company before founding Quincy Biosciences in 2004—was finally seeing his hard work come to fruition. His company’s flagship product, a brain health supplement called Prevagen, had made the leap

All access premium subscription

This content requires a subscription to Nutrition Business Journal.

As an NBJ subscriber, you receive 10 issues a year and access to the exclusive “NBJ subscriber only” content on newhope.com (excludes three-month subscriptions), which includes PowerPoint presentations, select data charts and archived articles. Subscribers also receive a 10 percent discount on data charts, comprehensive market research reports and webinars.

Email [email protected] for more information about subscribing.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish